Elafin is a biomarker of graft-versus-host disease of the skin

Sophie Paczesny; Thomas M. Braun; John E. Levine; Jason Hogan; Jeffrey Crawford; Bryan Coffing; Stephen Olsen; Sung W. Choi; Hong Wang; Vitor Faca; Sharon Pitteri; Qing Zhang; Alice Chin; Carrie Kitko; Shin Mineishi; Gregory Yanik; Edward Peres; David Hanauer; Ying Wang; Pavan Reddy; Samir Hanash; James L.M. Ferrara

doi:10.1126/scitranslmed.3000406

Elafin is a biomarker of graft-versus-host disease of the skin

Sophie Paczesny, Thomas M. Braun, John E. Levine, Jason Hogan, Jeffrey Crawford, Bryan Coffing, Stephen Olsen, Sung W. Choi, Hong Wang, Vitor Faca, Sharon Pitteri, Qing Zhang, Alice Chin, Carrie Kitko, Shin Mineishi, Gregory Yanik, Edward Peres, David Hanauer, Ying Wang, Pavan ReddySamir Hanash, James L.M. Ferrara

Research output: Contribution to journal › Article › peer-review

200 Scopus citations

Abstract

Graft-versus-host disease (GVHD), the major complication of allogeneic bone marrow transplantation, affects the skin, liver, and gastrointestinal tract. There are no plasma biomarkers specific for any acute GVHD target organ. We used a large-scale quantitative proteomic discovery procedure to identify biomarker candidates of skin GVHD and validated the lead candidate, elafin, with enzyme-linked immunosorbent assay in samples from 492 patients. Elafin was overexpressed in GVHD skin biopsies. Plasma concentrations of elafin were significantly higher at the onset of skin GVHD, correlated with the eventual maximum grade of GVHD, and were associated with a greater risk of death relative to other known risk factors (hazard ratio, 1.78). We conclude that elafin has significant diagnostic and prognostic value as a biomarker of skin GVHD.

Original language	English (US)
Pages (from-to)	13ra2
Journal	Science Translational Medicine
Volume	2
Issue number	13
DOIs	https://doi.org/10.1126/scitranslmed.3000406
State	Published - 2010

All Science Journal Classification (ASJC) codes

General Medicine

Access to Document

10.1126/scitranslmed.3000406

Cite this

Paczesny, S., Braun, T. M., Levine, J. E., Hogan, J., Crawford, J., Coffing, B., Olsen, S., Choi, S. W., Wang, H., Faca, V., Pitteri, S., Zhang, Q., Chin, A., Kitko, C., Mineishi, S., Yanik, G., Peres, E., Hanauer, D., Wang, Y., ... Ferrara, J. L. M. (2010). Elafin is a biomarker of graft-versus-host disease of the skin. Science Translational Medicine, 2(13), 13ra2. https://doi.org/10.1126/scitranslmed.3000406

@article{b931a2331ae944e99218662e3c8e6928,

title = "Elafin is a biomarker of graft-versus-host disease of the skin",

abstract = "Graft-versus-host disease (GVHD), the major complication of allogeneic bone marrow transplantation, affects the skin, liver, and gastrointestinal tract. There are no plasma biomarkers specific for any acute GVHD target organ. We used a large-scale quantitative proteomic discovery procedure to identify biomarker candidates of skin GVHD and validated the lead candidate, elafin, with enzyme-linked immunosorbent assay in samples from 492 patients. Elafin was overexpressed in GVHD skin biopsies. Plasma concentrations of elafin were significantly higher at the onset of skin GVHD, correlated with the eventual maximum grade of GVHD, and were associated with a greater risk of death relative to other known risk factors (hazard ratio, 1.78). We conclude that elafin has significant diagnostic and prognostic value as a biomarker of skin GVHD.",

author = "Sophie Paczesny and Braun, {Thomas M.} and Levine, {John E.} and Jason Hogan and Jeffrey Crawford and Bryan Coffing and Stephen Olsen and Choi, {Sung W.} and Hong Wang and Vitor Faca and Sharon Pitteri and Qing Zhang and Alice Chin and Carrie Kitko and Shin Mineishi and Gregory Yanik and Edward Peres and David Hanauer and Ying Wang and Pavan Reddy and Samir Hanash and Ferrara, {James L.M.}",

year = "2010",

doi = "10.1126/scitranslmed.3000406",

language = "English (US)",

volume = "2",

pages = "13ra2",

journal = "Science Translational Medicine",

issn = "1946-6234",

publisher = "American Association for the Advancement of Science",

number = "13",

}

Paczesny, S, Braun, TM, Levine, JE, Hogan, J, Crawford, J, Coffing, B, Olsen, S, Choi, SW, Wang, H, Faca, V, Pitteri, S, Zhang, Q, Chin, A, Kitko, C, Mineishi, S, Yanik, G, Peres, E, Hanauer, D, Wang, Y, Reddy, P, Hanash, S & Ferrara, JLM 2010, 'Elafin is a biomarker of graft-versus-host disease of the skin', Science Translational Medicine, vol. 2, no. 13, pp. 13ra2. https://doi.org/10.1126/scitranslmed.3000406

TY - JOUR

T1 - Elafin is a biomarker of graft-versus-host disease of the skin

AU - Paczesny, Sophie

AU - Braun, Thomas M.

AU - Levine, John E.

AU - Hogan, Jason

AU - Crawford, Jeffrey

AU - Coffing, Bryan

AU - Olsen, Stephen

AU - Choi, Sung W.

AU - Wang, Hong

AU - Faca, Vitor

AU - Pitteri, Sharon

AU - Zhang, Qing

AU - Chin, Alice

AU - Kitko, Carrie

AU - Mineishi, Shin

AU - Yanik, Gregory

AU - Peres, Edward

AU - Hanauer, David

AU - Wang, Ying

AU - Reddy, Pavan

AU - Hanash, Samir

AU - Ferrara, James L.M.

PY - 2010

Y1 - 2010

N2 - Graft-versus-host disease (GVHD), the major complication of allogeneic bone marrow transplantation, affects the skin, liver, and gastrointestinal tract. There are no plasma biomarkers specific for any acute GVHD target organ. We used a large-scale quantitative proteomic discovery procedure to identify biomarker candidates of skin GVHD and validated the lead candidate, elafin, with enzyme-linked immunosorbent assay in samples from 492 patients. Elafin was overexpressed in GVHD skin biopsies. Plasma concentrations of elafin were significantly higher at the onset of skin GVHD, correlated with the eventual maximum grade of GVHD, and were associated with a greater risk of death relative to other known risk factors (hazard ratio, 1.78). We conclude that elafin has significant diagnostic and prognostic value as a biomarker of skin GVHD.

AB - Graft-versus-host disease (GVHD), the major complication of allogeneic bone marrow transplantation, affects the skin, liver, and gastrointestinal tract. There are no plasma biomarkers specific for any acute GVHD target organ. We used a large-scale quantitative proteomic discovery procedure to identify biomarker candidates of skin GVHD and validated the lead candidate, elafin, with enzyme-linked immunosorbent assay in samples from 492 patients. Elafin was overexpressed in GVHD skin biopsies. Plasma concentrations of elafin were significantly higher at the onset of skin GVHD, correlated with the eventual maximum grade of GVHD, and were associated with a greater risk of death relative to other known risk factors (hazard ratio, 1.78). We conclude that elafin has significant diagnostic and prognostic value as a biomarker of skin GVHD.

UR - http://www.scopus.com/inward/record.url?scp=77952962428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952962428&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3000406

DO - 10.1126/scitranslmed.3000406

M3 - Article

C2 - 20371463

AN - SCOPUS:77952962428

SN - 1946-6234

VL - 2

SP - 13ra2

JO - Science Translational Medicine

JF - Science Translational Medicine

IS - 13

ER -

Elafin is a biomarker of graft-versus-host disease of the skin

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this